

# More evidence evolocumab exceeds cost-effectiveness

August 25 2017

---



(HealthDay)—At its current price, the addition of evolocumab to

standard therapy in patients with atherosclerotic cardiovascular disease generally exceeds accepted cost-effectiveness thresholds, according to a study published online Aug. 23 in *JAMA Cardiology*.

Gregg C. Fonarow, M.D., from the Ronald Reagan University of California in Los Angeles, and colleagues examined the cost-effectiveness of evolocumab in [patients](#) with [atherosclerotic cardiovascular disease](#). A Markov cohort state-transition model was used, which included U.S. population-specific demographics, risk factors, background therapy, and event rates, as well as trial-based event risk reduction.

The researchers found that evolocumab was associated with increased cost and improved quality-adjusted life-year (QALY) in the base case, using U.S. clinical practice patients with atherosclerotic cardiovascular disease with [low-density lipoprotein cholesterol](#) levels of  $\geq 70$  mg/dL and an annual events rate of 6.4 per 100 patient-years: incremental cost \$105,398; incremental QALY, 0.39, with an incremental cost effectiveness ratio (ICER) of \$268,637 per QALY gained. ICERs varied from \$100,193 to \$488,642 per QALY in sensitivity and scenario analyses, with ICER of \$413,579 per QALY for trial patient characteristics and event rate of 4.2 per 100 patient-years. In most scenarios, evolocumab treatment exceeded \$150,000 per QALY.

"To achieve an ICER of \$150,000 per QALY, the annual net price would need to be substantially lower (\$9,669 for U.S. clinical practice and \$6,780 for trial participants), or a higher-risk population would need to be treated," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Amgen, which manufactures evolocumab and funded the study.

**More information:** [Abstract/Full Text](#)  
[Editorial](#)

Copyright © 2017 [HealthDay](#). All rights reserved.

Citation: More evidence evolocumab exceeds cost-effectiveness (2017, August 25) retrieved 24 January 2023 from <https://medicalxpress.com/news/2017-08-evidence-evolocumab-cost-effectiveness.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.